ARTICLE | Product Development
Solving AAV’s one-and-done problem: ASGCT highlights
Strategies to enable redosing and overcome pre-existing immunity could help revive interest in rare disease gene therapy
May 12, 2026 1:12 AM UTC
Updated on May 15, 2026 at 8:04 PM UTC
Solving AAV’s redosing problem could change the economics of rare disease gene therapy and reignite industry interest in a modality that has fallen out of favor. The concept, a hot topic at this week’s ASGCT conference, is creeping closer to reality.
The 2026 American Society of Gene & Cell Therapy (ASGCT) meeting will feature at least 12 preclinical presentations that describe strategies to enable repeat dosing or overcome pre-existing immunity to AAV vectors...